摘要
目的探讨Hsp70、Fas和FasL在乳腺癌中的表达及其在乳腺癌发生发展中的作用。方法用免疫组织化学和Westernblot法检测30例乳腺癌标本中Hsp70、Fas和FasL的表达,流式细胞术检测乳腺癌细胞DNA指数(DNAindex,DI)和凋亡指数(apoptosisindex,AI)。结果Hsp70、Fas和FasL在乳腺癌、癌旁乳腺组织中阳性率分别为93.3%和60.0%、53.3%和96.7%、93.3%和63.3%,各组差异有显著性。Fas在乳腺癌中呈低表达,在癌旁乳腺组织中呈高表达;而Hsp70和FasL在乳腺癌中呈高表达,在癌旁乳腺组织中呈低表达。乳腺癌、癌旁乳腺组织DI分别为1.29±0.16和0.99±0.44(t=9.974,P=0.000);AI分别为7.23±0.55和9.99±0.52(t=11.56,P=0.000),差异有显著性。结论在乳腺癌中Fas呈低表达,Hsp70和FasL呈高表达;乳腺癌凋亡程度显著低于癌旁组织;Fas下调、Hsp70及FasL上调可能促进乳腺癌的发生发展。
Objective To evaluate the altered expression of Hsp70,Fas and FasL in breast cancer and their role in the occurrence and progression of breast cancer.Methods The expression of Hsp70,Fas and FasL was analyzed by immunohistochemistry (IHC) and Western blot in 30 cases of breast cancer.The DNA index (DI) and apoptosis index (AI) of breast cancer cells were analyzed by the flow cytometry (FCM).Results The rates of expression of Hsp70,Fas and FasL in the breast carcinoma tissue and the surrounding non-cancerous tissue were 93.3%,60.0%;53.3%,96.7%;93.3%,63.3% respectively. The difference between the breast carcinoma tissue and the surrounding non-cancerous tissue was significant. The level of expression of Fas was low in breast carcinoma tissue, nevertheless,it was very high in the surrounding non-cancerous tissue.The levels of expression of Hsp70 and FasL were high in breast carcinoma tissue,while they were low in the surrounding non-cancerous tissue.The DI of breast carcinoma tissue and the surrounding non-cancerous tissue was 1.29±0.16 and 0.99±0.44 respectively(t=9.974,P=0.000);the AI was 7.23±0.55 and 9.99±0.52 respectively(t=11.56,P=~0.000 );the differences were statistically significant.Conclusion The level of expression of Fas is low in breast cancer,while that of Hsp70 and FasL is high.The degree of apoptosis in breast cancer is significantly lower than that in the surrounding non-cancerous tissue. The down-regulation of Fas and the up-regulation of Hsp70 and FasL may facilitate the progression of breast cancer.
出处
《中国肿瘤临床与康复》
2005年第3期193-196,共4页
Chinese Journal of Clinical Oncology and Rehabilitation
